Under the deal, BioQuiddity will secure the requisite regulatory approvals and supplying the unit-dose infusion systems, while Sandoz is responsible to market and commercialize BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products.
BioQuiddity president and CEO Josh Kriesel said: "We are thrilled to collaborate with Sandoz, a proven leader in the healthcare industry.
"Our ready-to-use drug delivery platform provides a therapy specific solution that is immediately deployable at the point of care without multiple preparation steps.
"We look forward to rapidly offering a portfolio of innovative cost effective infusion solutions in the US through this collaboration."
BioQuiddity’s infusion platform addresses some of the most pressing unmet needs in drug infusion including cost, medication error, sterility, efficiency and patient quality of life.